KingKong88
2021-08-02
Hmm...
[思考]
Goldman Sachs picks new stocks to buy from tech to health — some with over 100% upside
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
3
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":805649694,"tweetId":"805649694","gmtCreate":1627878916018,"gmtModify":1633755660612,"author":{"id":3581844366704770,"authorId":3581844366704770,"authorIdStr":"3581844366704770","name":"KingKong88","avatar":"https://static.tigerbbs.com/ca221e1f8c3c6fd2bccd3f8d4d7b5bdb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hmm... <span>[思考] </span></p></body></html>","htmlText":"<html><head></head><body><p>Hmm... <span>[思考] </span></p></body></html>","text":"Hmm... [思考]","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/805649694","repostId":1125617093,"repostType":4,"repost":{"id":"1125617093","pubTimestamp":1627875620,"share":"https://www.laohu8.com/m/news/1125617093?lang=&edition=full","pubTime":"2021-08-02 11:40","market":"us","language":"en","title":"Goldman Sachs picks new stocks to buy from tech to health — some with over 100% upside","url":"https://stock-news.laohu8.com/highlight/detail?id=1125617093","media":"CNBC","summary":"Goldman Sachs has added a slew of new stocks to its coverage, ranging from tech companies to health ","content":"<div>\n<p>Goldman Sachs has added a slew of new stocks to its coverage, ranging from tech companies to health care firms and media businesses. Of the more than 70 stocks it started researching in July, it is ...</p>\n\n<a href=\"https://www.cnbc.com/2021/08/02/goldman-sachs-picks-new-stocks-to-buy-from-tech-to-health.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs picks new stocks to buy from tech to health — some with over 100% upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs picks new stocks to buy from tech to health — some with over 100% upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 11:40 GMT+8 <a href=https://www.cnbc.com/2021/08/02/goldman-sachs-picks-new-stocks-to-buy-from-tech-to-health.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Goldman Sachs has added a slew of new stocks to its coverage, ranging from tech companies to health care firms and media businesses. Of the more than 70 stocks it started researching in July, it is ...</p>\n\n<a href=\"https://www.cnbc.com/2021/08/02/goldman-sachs-picks-new-stocks-to-buy-from-tech-to-health.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEVI":"李维斯","LYV":"Live Nation Entertainment","AMAM":"Ambrx Biopharma Inc","PVH":"PVH Corp","TASK":"TaskUs Inc.","IS":"IronSource Ltd","ZM":"Zoom","GS":"高盛","RL":"拉夫劳伦","S":"SentinelOne, Inc","IHRT":"iHeartMedia, Inc.","02618":"京东物流","02171":"科济药业-B","LYEL":"Lyell Immunopharma, Inc.","LULU":"lululemon athletica"},"source_url":"https://www.cnbc.com/2021/08/02/goldman-sachs-picks-new-stocks-to-buy-from-tech-to-health.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1125617093","content_text":"Goldman Sachs has added a slew of new stocks to its coverage, ranging from tech companies to health care firms and media businesses. Of the more than 70 stocks it started researching in July, it is buy-rated on about 45 — and some have a potential upside of over 100%.\nGoldman’s analysts initiated coverage on newly-listed companies that debuted on the stock market in the past few months, and also started providing research on some big-name apparel and media brands. Here’s a selection.\nHealth care\nU.S. insurance firm Bright Health Group, which operates insurance tech software as well as a platform connecting patients with health providers is buy-rated by the bank and raised nearly $1 billionin an initial public offering (IPO) in May. Goldman said it sees more than 100% upside to the share price from its current levels over 12 months, while trading at a “healthy” discount to other rapidly-growing insurers, according to a July 19 research note.\nGoldman also likes Ambrx Biopharma Inc, a cancer biotech firm, for its “pioneering research”, “unique and differentiated platform technology” and partnerships with pharmaceuticals companies such as Bristol Myers Squibb. The bank’s 12-month price target is $53, representing a 148.8% potential upside, the analysts said in a July 13 research note.\nHealth tech company Convey Holding Parent, Inc., which counts the likes of U.S. government insurance plan Medicare as a customer, is a buy for the bank. “We believe Convey differentiates itself from competitors as a provider of purpose-built healthcare IT software and services to government-sponsored health plans,” Goldman’s analysts wrote in a July 11 research note. The bank’s 12-month price target is $21, representing a potential 112.6% upside.\nLyell Immunopharma, Inc., which develops cancer therapies, is also buy-rated by the analysts. “We are encouraged by the preclinical data seen to-date and the experienced management team and note multiple programs are set to enter the clinic with first-in-human data next year,” Goldman’s analysts said in a July 12 research note. The bank’s 12-month price target is $30, representing a potential upside of 88.9%.\nOther new healthcare stocks Goldman picked include Chinese biotech firm CARSGEN-B, with a 12-month price target of 48.72 Hong Kong dollars ($6.25) — a potential upside of 62.7% — and Chinese firm AmoyDx, with a 12-month price target of 140 yuan renminbi ($21.52), a potential upside of 66.7%.\nTechnology\nDigital support company TaskUs Inc. is buy-rated, with Goldman giving it a 12-month price target of $61, a potential upside of 88.3%. The firm helps manage customer service for the likes of Zoom, which hired the company as the coronavirus pandemic struck in 2020. “We believe there is potential, given its historically high net retention rate, for it to grow above the consensus growth rates of its clients,” the bank’s analysts wrote in a July 6 note.\nGoldman gave IronSource Ltd, a “fast growing mobile ad platform at scaled margins,” a 12-month price target of $11, a potential upside of 23.7%. The company went public in Marchvia a special-purpose acquisition vehicle (SPAC)and the bank said it would benefit from growth in mobile apps and also liked its game development arm Sonic Publishing.\nSentinelOne, Inc, which debuted on the New York Stock Exchange in June and wasthe highest-valued cybersecurity IPO ever, is also buy-rated by the bank. Goldman described it as “a best of breed, founder-led XDR [extended detection and response] leader in one of the most attractive segments within Security Software,” in a July 25 research note. The bank gave the stock a 12-month price target of $57, a potential upside of 22.4%.\nGoldman also picked “leading” Chinese firm JD LOGISTICS— which became a separate entity to retail giant JD.com in 2017 — andlisted on the Hong Kong stock exchange in May. Goldman expects it to double its market share by 2025, growing via investments in supply chain technology, overseas expansion and additions to its air cargo network. The bank’s 12-month price target is 58.50 Hong Kong dollars, representing a potential upside of 38.3%.\nGoldman also likes Nasdaq-listed Turkish e-commerce giant Hepsiburada, with a 12-month price target of $25.90 — a potential upside of 95% — and Chinese electronics seller AiHuiShou, with a 12-month price target of $20.80, representing a potential upside of 48.1%.\nApparel\nGoldman started covering several apparel stocks this month and said the sector has “macro tailwinds from a strong consumer and supportive discretionary retail spend,” in a July 14 note to investors.\nAthleisure company Lululemon Athletica on Goldman’s conviction list, with the bank describing it as “a leader in driving online to offline consumer connection,” giving it a buy rating. The analysts likedits $500 million acquisition of fitness screen company Mirror, and gave the stock a $447 12-month target price, a potential upside of 21%.\nLuxury label Ralph Lauren has “potential upside” from digital sales via its own websites, according to Goldman, which is “upbeat” about the company’s turnaround, and it gave it a buy rating. The bank’s 12-month price target is $147, a potential upside of 28%.\nGoldman is also buy-rated on Calvin Klein owner PVH Corp, due to the company’s e-commerce focus, new management and pandemic restructuring, expecting the firm to provide “stronger” margins. The bank gave the stock a 12-month price target of $127, a potential upside of 21%.\nLevi Strauss & Co is a buy for the bank, which liked its “best-in-class heritage positioning.” “LEVI is emerging from the pandemic with a better-positioned US wholesale marketplace, a more agile organization with increased digital tools and a faster go-to-market,” Goldman said. Its 12-month price target is $36, a potential upside of 25%.\nMedia\nGoldman started covering concert promoter Live Nation Entertainment on July 15. “We initiate coverage on Live Nation (“LYV”) with a Buy rating and 12-month price target of $110, implying 35% total potential return,” the bank said. Goldman expects an uptick inlive events after the pandemicand sees growth opportunities in high-margin merchandise and VIP experiences.\nThe bank also likes audio firm iHeartMedia, Inc., calling it a “most undiscovered” stock, and “the leading multi-platform audio media company in the U.S.” “We initiate coverage on iHeartMedia (“IHRT”) with a Buy rating and a 12-month price target of $32, representing 25% total potential return,” the analysts said in a July 15 research note.","news_type":1},"isVote":1,"tweetType":1,"viewCount":810,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/805649694"}
精彩评论